Xtant Medical Inc. (XTNT)
Xtant Medical Inc. (XTNT) Stock Price, Analysis & Data
| Bid | 0.31 |
| Market Cap | 42.87M |
| Revenue (ttm) | 109.53M |
| Net Income (ttm) | -11.14M |
| Beta | n/a |
| EPS (ttm) | -0.08 |
| PE Ratio (ttm) | n/a |
| Forward PE | -5.09 |
| P/B (ttm) | 1.07 |
| P/S (ttm) | 0.39 |
| Earnings Date | Nov 9, 2023 |
| Ask | 0.31 |
| Volume | 527,161 |
| Avg. Volume (20D) | 119,937 |
| Open | 0.30 |
| Previous Close | 0.32 |
| Day's Range | 0.27 - 0.32 |
| 52-Week Range | 0.27 - 0.95 |
| Analyst | n/a |
| Price Target | 1.35 (335.48%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About XTNT
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of a...
Financial Performance
In 2025, Xtant Medical's revenue was 133.93M, an increase of 14.21% compared to the previous year's 117.27M. Earnings were 4.97M, a decrease of -130.23%.
Financial StatementsAnalyst Forecast
According to 2 analyst ratings, the average rating for XTNT stock is "null". The 12-month stock price forecast is 1.35, which is upside of 335.48% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
